A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up

被引:0
作者
Gross, N. [1 ]
Miller, D. M. [2 ]
Khushalani, N. I. [3 ]
Divi, V. [4 ]
Ruiz, E. [5 ]
Lipson, E. J. [6 ,7 ]
Meier, F. [8 ]
Su, Y. B. [9 ]
Swiecicki, P. L. [10 ]
Atlas, J. L. [11 ]
Geiger, J. L. [12 ]
Hauschild, A. [13 ]
Choe, J. H. [14 ]
Hughes, B. G. M. [15 ,16 ]
Yoo, S. Y. [17 ]
Mathias, M. D. [18 ]
Han, H. [18 ]
Fury, M. G. [18 ]
Rischin, D. [1 ,19 ,20 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Head & Neck Surg, Houston, TX USA
[2] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[4] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, Stanford, CA USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA
[6] Johns Hopkins, Bloombergw Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[7] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Univ Klinikum Carl Gustav Carus Dresden, Dept Dermatol, Skin Canc Ctr, Natl Ctr Tumor Dis, Dresden, Germany
[9] Nebraska Canc Specialists Midwest Canc Ctr Legacy, Head & Neck Med Oncol, Omaha, NE USA
[10] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[11] Atrium Hlth, Levine Canc Inst, Carolinas HealthCare Syst, Charlotte, NC USA
[12] Cleveland Clin, Solid Tumor Oncol, Cleveland, OH USA
[13] Schleswig Holstein Univ Hosp, Dept Dermatol, Kiel, Germany
[14] Duke Canc Inst, Med Oncol, Durham, NC USA
[15] Royal Brisbane & Womens Hosp, Dept Canc Care Serv, Herston, Qld, Australia
[16] Univ Queensland, Herston, Qld, Australia
[17] Regeneron Pharmaceut Inc, Biostat, Tarrytown, NY USA
[18] Regeneron Pharmaceut Inc, Dept Oncol, Tarrytown, NY USA
[19] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[20] Univ Melbourne, Melbourne, Vic, Australia
关键词
D O I
10.1016/j.annonc.2023.09.2222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
1088MO
引用
收藏
页码:S655 / S655
页数:1
相关论文
empty
未找到相关数据